PHMR

New HTA Decisions in Germany

December 2021

Drug name

ANGUSTA® (misoprostol)

Company

Norgine GmbH

Decision date

01/12/2021

Our experience

Therapeutic area

Fertility, pregnancy and childbirth

Therapeutic sub area

Intrapartum care

G-BA decision date

15/02/2022

Orphan Drug?

Decision
No additional benefit
Indication
Induction of labour in the event of immature cervix.

Appropriate comparator therapy: dinoprostone

Decision Detail

Main study: Young 2020 Main driver of decision: There was no suitable data provided for the intervention or comparator therapy.

Summary

IQWIG concluded that there was no added benefit.

Our experience